Prostate Cancer | Specialty

Dr. Sandler Discusses Hypofractionation in Prostate Cancer

March 8th 2018

Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

Apalutamide Approval Paves Way for Further Advances in Nonmetastatic CRPC

March 7th 2018

Alan H. Bryce, MD, discusses emerging agents and next steps in the treatment of patients with in nonmetastatic prostate cancer.

Surgery, Brachytherapy-based Radiotherapy Induce Similar Survival in Localized Prostate Cancer

March 7th 2018

Investigators found no statistically significant difference in survival between radical prostatectomy alone and external beam radiotherapy plus brachytherapy with or without ADT after adjusting for imbalances in prostate cancer prognostic factors.

Risk Stratification Critical to Optimal Prostate Cancer Care

March 6th 2018

Erik P. Castle, MD, discusses the importance of risk stratifying low- and intermediate-risk localized prostate cancers.

Expert Addresses Abiraterone Versus Docetaxel in Castration-Sensitive Prostate Cancer

March 5th 2018

Julie Graff, MD, shares her insight on pivotal trials exploring abiraterone acetate (Zytiga) and docetaxel in this in patients with castration-sensitive prostate cancer.

A Call to Arms in Urology

March 4th 2018

Prostate cancer continues to be the most common newly diagnosed solid tumor in men over 50 years and the second leading cause of cancerspecific mortality.

Dr. Graff on the Use of Abiraterone in Metastatic Prostate Cancer

March 3rd 2018

Julie N. Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses treatment for patients with high-risk metastatic disease following the FDA approval of abiraterone acetate (Zytiga).

Dr. Freedland on Diet and Lifestyle Interventions in Patients With Prostate Cancer

March 1st 2018

Stephen J. Freedland, MD, director, Center for Integrated Research in Cancer and Lifestyle, co-director, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, professor of surgery, Cedars-Sinai Medical Center, discusses nuanced diet and lifestyle interventions in patients with prostate cancer.

Dr. Daskivich on Imaging Modalities in Prostate Cancer

March 1st 2018

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses developing and available imaging modalities in prostate cancer.

Dr. Posadas on the Use of Circulating Tumor Cells in mCRPC

March 1st 2018

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses the future of detection in metastatic castration-resistant prostate cancer (mCRPC).

Limitations in the Management of NETs

March 1st 2018

Developments in the NETs Treatment Landscape

March 1st 2018

Role of PRRT in the Management of NETs

March 1st 2018

Deciding on SSA Treatment in NETs

March 1st 2018

Overview of Somatostatin Analogs for NETs

March 1st 2018

Symptom Control in Functional NETs

March 1st 2018

Risk Stratification and Management of NETs

March 1st 2018

Surgical Considerations for Neuroendocrine Tumors

March 1st 2018

Advances in the Management of NETs

March 1st 2018

Degarelix May Reduce Risk of Cardiovascular Events in Prostate Cancer

February 27th 2018

Susan F. Slovin, MD, PhD, discusses the multinational PRONOUNCE study and how the results may affect the treatment of patients with prostate cancer.